Literature DB >> 8448065

Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

D Wu1, S V Otton, B A Sproule, U Busto, T Inaba, W Kalow, E M Sellers.   

Abstract

1. In microsomes prepared from three human livers, methadone competitively inhibited the O-demethylation of dextromethorphan, a marker substrate for CYP2D6. The apparent Ki value of methadone ranged from 2.5 to 5 microM. 2. Two hundred and fifty-two (252) white Caucasians, including 210 unrelated healthy volunteers and 42 opiate abusers undergoing treatment with methadone were phenotyped using dextromethorphan as the marker drug. Although the frequency of poor metabolizers was similar in both groups, the extensive metabolizers among the opiate abusers tended to have higher O-demethylation metabolic ratios and to excrete less of the dose as dextromethorphan metabolites than control extensive metabolizer subjects. These data suggest inhibition of CYP2D6 by methadone in vivo as well. 3. Because methadone is widely used in the treatment of opiate abuse, inhibition of CYP2D6 activity in these patients might contribute to exaggerated response or unexpected toxicity from drugs that are substrates of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8448065      PMCID: PMC1381486          DOI: 10.1111/j.1365-2125.1993.tb05666.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

1.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  The biotransformation of methadone in man: synthesis and identification of a major metabolite.

Authors:  A H Beckett; J F Taylor; A F Casy; M M Hassan
Journal:  J Pharm Pharmacol       Date:  1968-10       Impact factor: 3.765

3.  The levels of methadone in the plasma in methadone maintenance.

Authors:  C E Inturrisi; K Verebely
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

4.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

5.  Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.

Authors:  A R Boobis; S Murray; G C Kahn; G M Robertz; D S Davies
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

6.  Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1983-02-14       Impact factor: 5.037

7.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

8.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

9.  Impact of environmental and genetic factors on codeine analgesia.

Authors:  J Desmeules; M P Gascon; P Dayer; M Magistris
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.

Authors:  I Kitchen; J Tremblay; J André; L G Dring; J R Idle; R L Smith; R T Williams
Journal:  Xenobiotica       Date:  1979-07       Impact factor: 1.908

View more
  22 in total

Review 1.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.

Authors:  Janet K Coller; Jennifer R Michalakas; Heather M James; Aaron L Farquharson; Joel Colvill; Jason M White; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 3.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.

Authors:  D J Foster; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

5.  Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.

Authors:  Ping Liu; Grover Foster; Robert Labadie; Eugene Somoza; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

8.  A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.

Authors:  M R Shiran; J Chowdry; A Rostami-Hodjegan; S W Ellis; M S Lennard; M Z Iqbal; O Lagundoye; N Seivewright; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

9.  An in vitro approach to potential methadone metabolic-inhibition interactions.

Authors:  Stephanie Bomsien; Gisela Skopp
Journal:  Eur J Clin Pharmacol       Date:  2007-06-28       Impact factor: 2.953

10.  The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.

Authors:  N L Kerry; A A Somogyi; F Bochner; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.